Allogene Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Allogene Therapeutics, Inc. (ALLO) had Operating Lease, Weighted Average Discount Rate, Percent of 6.51% as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 6.51%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 6.50%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 6.49%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 6.28%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 6.51% 10-Q · filed 2026-08-12 |
| 2026-03-31 | 6.50% 10-Q · filed 2026-05-13 |
| 2025-12-31 | 6.49% 10-K · filed 2026-03-12 |
| 2025-09-30 | 6.28% 10-Q · filed 2025-11-06 |
| 2025-06-30 | 6.27% 10-Q · filed 2025-08-13 |
| 2025-03-31 | 6.26% 10-Q · filed 2025-05-13 |
| 2024-12-31 | 6.26% 10-K · filed 2025-03-13 |
| 2024-09-30 | 6.25% 10-Q · filed 2024-11-07 |
| 2024-06-30 | 6.24% 10-Q · filed 2024-08-07 |
| 2024-03-31 | 6.24% 10-Q · filed 2024-05-13 |
| 2023-12-31 | 6.22% 10-K · filed 2024-03-14 |
| 2023-09-30 | 6.89% 10-Q · filed 2023-11-02 |
| 2023-06-30 | 6.88% 10-Q · filed 2023-08-02 |
| 2023-03-31 | 6.88% 10-Q · filed 2023-05-03 |
| 2022-12-31 | 6.20% 10-K/A · filed 2024-03-14 |
| 2022-09-30 | 6.19% 10-Q · filed 2022-11-02 |
| 2022-06-30 | 6.19% 10-Q · filed 2022-08-09 |
| 2022-03-31 | 6.36% 10-Q · filed 2022-05-04 |
| 2021-12-31 | 6.34% 10-K · filed 2022-02-23 |
| 2021-09-30 | 8.43% 10-Q · filed 2021-11-04 |
| 2021-06-30 | 8.42% 10-Q · filed 2021-08-04 |
| 2021-03-31 | 8.40% 10-Q · filed 2021-05-05 |
| 2020-12-31 | 8.37% 10-K · filed 2021-02-25 |
| 2020-09-30 | 8.36% 10-Q · filed 2020-11-04 |
| 2020-06-30 | 8.35% 10-Q · filed 2020-08-05 |
| 2020-03-31 | 8.34% 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |